论文部分内容阅读
血红蛋白分子病是近年来普遍地引起国内外遗传学,生物化学,血液学及临床等领域重视和研究的遗传性贫血。广东为地中海贫血高发地区之一。近年由于诊断技术的提高,病人不断增加,治疗问题成为迫切需要解决的问题。目前,国外对地中海贫血的治疗采用定期大量输血配合铁螯合剂疗法,使患者的血红蛋白保持在10克以上的水平,取得一定的效果。但此种疗法在国内,尤其是农村尚难推广使用,本文综合广东省人民医院,中山医学院附属一院及二院,近20年来成年人地中海贫血30例脾切除术后的临床资料,探讨其疗效,现报告如下:
Hemoglobin molecular disease is a hereditary anemia that has aroused widespread attention and research in the field of genetics, biochemistry, hematology and clinical at home and abroad in recent years. Guangdong is one of the most endemic areas of thalassemia. In recent years, due to the improvement of diagnostic techniques, the number of patients continues to increase, and the treatment problem has become an urgent problem to be solved. At present, the treatment of thalassemia abroad by regular massive blood transfusion with iron chelator therapy, so that patients with hemoglobin at 10 grams and above, and achieved some results. However, this kind of therapy is hard to be promoted and used in China, especially in rural areas. This article summarizes the clinical data of 30 cases of thalassemia after splenectomy in Guangdong Provincial People’s Hospital, First Affiliated Hospital of Zhongshan Medical College and Second Hospital in recent 20 years Its efficacy, are as follows: